Arterial Occlusive Disease Clinical Trial
Official title:
Infrapopliteal Drug Eluting Angioplasty Versus Stenting for the Treatment of Long-segment Arterial Disease: The IDEAS-I Randomized Controlled Trial.
In total 50 patients diagnosed with long-segment infrapopliteal arterial disease will be randomized in two groups. The patients randomized in the Drug coated balloons (DCB) study arm will undergo a percutaneous transluminal angioplasty (PTA) with the use of a paclitaxel-coated balloon, while the patients randomized in the drug-eluting stent (DES) study arm will undergo primary stenting using drug-eluting stent(s). The study's primary endpoints will be the 6-month angiographic binary restenosis rate. Secondary endpoints will include the immediate technical success,6-month primary patency, target lesion revascularization and limb salvage and complication rates.
Patients programmed to undergo PTA due to angiographically-proven infrapopliteal arterial disease in our department will be randomized in the above mentioned study arms. The studies primary endpoint will be assessed with the use of intra-arterial digital subtracted angiography and subsequent Quantitative Vascular Analysis (QVA) analysis.Clinical follow-up is set at 1, 3 and 6 months. Patients' baseline demographics and procedural details will be recorded and analyzed. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02228564 -
BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
|
N/A | |
| Withdrawn |
NCT01002209 -
Postoperative Hyperbaric Oxygen Treatments to Reduce Complications in Diabetic Patients Undergoing Vascular Surgery
|
Phase 2/Phase 3 | |
| Completed |
NCT02255188 -
Experimental Study of the Vascular Prosthesis Manufactured by Electrospinning
|
N/A | |
| Terminated |
NCT00913900 -
Safety Study of Adult Stem Cells to Treat Patients With Severe Leg Artery Disease
|
Phase 1 | |
| Completed |
NCT01548378 -
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
|
Phase 2 | |
| Completed |
NCT00447889 -
A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR) Angiography
|
Phase 4 | |
| Terminated |
NCT00823225 -
Urokinase Therapy in Patients With Diabetic Foot Syndrome
|
Phase 3 | |
| Terminated |
NCT00403780 -
Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia
|
Phase 4 | |
| Completed |
NCT00817349 -
Angio-Seal Evolution Device Registry
|
||
| Completed |
NCT00673985 -
Edwards Lifesciences Self-Expanding Stent Peripheral Vascular Disease Study
|
N/A | |
| Active, not recruiting |
NCT02685098 -
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
|
Phase 1 | |
| Completed |
NCT00153166 -
ARREST PAD (Peripheral Arterial Disease)
|
Phase 2/Phase 3 | |
| Completed |
NCT00352222 -
Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries
|
Phase 3 | |
| Completed |
NCT00115856 -
Imaging of Plaque With Magnetic Resonance Imaging (MRI)
|
N/A | |
| Completed |
NCT00537498 -
Urokinase Therapy in Diabetic Foot Syndrome
|
Phase 2 | |
| Completed |
NCT01746550 -
A Safety and Effectiveness Study of the MD-12-001 Stent in the Treatment of Superficial Femoral Artery or Popliteal Artery Blockages in Japanese Patients
|
N/A | |
| Withdrawn |
NCT00407940 -
ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion
|
Phase 4 | |
| Completed |
NCT00489320 -
An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).
|
N/A | |
| Completed |
NCT00189540 -
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers
|
Phase 2 | |
| Recruiting |
NCT04275323 -
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1)
|
Phase 3 |